Study identifier:D356PL00015
ClinicalTrials.gov identifier:NCT04964544
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase III, 6-Month Self-selection and Actual Use Study for Rx-to-OTC Switch of rosuvastatin 5 mg once-daily in combination with a Web App
High Cholesterol
Phase 3
No
5 mg rosuvastatin calcium with a Web App (combination product)
All
1196
Interventional
20 Years - 75 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
Concentrics Research LLC, Concentrics Research - STATKING JV, Idea Evolver, Cleveland Clinic
No locations available
Arms | Assigned Interventions |
---|---|
Other: Open Label, Single Arm Technology-Assisted Cholesterol Trial Open Label Single Arm study in All-comers population who self-report having concern about high cholesterol or heart health | - |